Atria Wealth Solutions Inc. Decreases Position in Thermo Fisher Scientific Inc. $TMO

Atria Wealth Solutions Inc. trimmed its position in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 50.6% during the second quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 6,934 shares of the medical research company’s stock after selling 7,105 shares during the quarter. Atria Wealth Solutions Inc.’s holdings in Thermo Fisher Scientific were worth $2,819,000 at the end of the most recent reporting period.

A number of other institutional investors also recently bought and sold shares of TMO. Brighton Jones LLC boosted its position in Thermo Fisher Scientific by 28.9% during the fourth quarter. Brighton Jones LLC now owns 4,409 shares of the medical research company’s stock worth $2,293,000 after purchasing an additional 988 shares in the last quarter. Revolve Wealth Partners LLC lifted its position in shares of Thermo Fisher Scientific by 4.2% in the fourth quarter. Revolve Wealth Partners LLC now owns 491 shares of the medical research company’s stock valued at $255,000 after acquiring an additional 20 shares in the last quarter. GAMMA Investing LLC lifted its position in shares of Thermo Fisher Scientific by 22.0% in the first quarter. GAMMA Investing LLC now owns 4,862 shares of the medical research company’s stock valued at $2,419,000 after acquiring an additional 877 shares in the last quarter. Dynamic Advisor Solutions LLC purchased a new stake in shares of Thermo Fisher Scientific in the first quarter valued at $2,218,000. Finally, Mission Wealth Management LP lifted its position in shares of Thermo Fisher Scientific by 15.2% in the first quarter. Mission Wealth Management LP now owns 5,051 shares of the medical research company’s stock valued at $2,514,000 after acquiring an additional 668 shares in the last quarter. 89.23% of the stock is currently owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other Thermo Fisher Scientific news, EVP Gianluca Pettiti sold 400 shares of the company’s stock in a transaction dated Friday, July 25th. The stock was sold at an average price of $479.98, for a total transaction of $191,992.00. Following the completion of the sale, the executive vice president directly owned 22,367 shares in the company, valued at $10,735,712.66. This represents a 1.76% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, CAO Joseph R. Holmes sold 385 shares of the company’s stock in a transaction dated Friday, August 29th. The stock was sold at an average price of $492.63, for a total value of $189,662.55. Following the completion of the sale, the chief accounting officer directly owned 2,319 shares of the company’s stock, valued at $1,142,408.97. The trade was a 14.24% decrease in their position. The disclosure for this sale can be found here. Insiders sold 30,066 shares of company stock worth $14,182,963 over the last three months. 0.33% of the stock is owned by insiders.

Thermo Fisher Scientific Stock Performance

Thermo Fisher Scientific stock opened at $525.08 on Wednesday. The firm has a market capitalization of $198.28 billion, a P/E ratio of 30.37, a PEG ratio of 2.85 and a beta of 0.77. The stock has a fifty day moving average price of $491.00 and a 200 day moving average price of $448.20. Thermo Fisher Scientific Inc. has a 52 week low of $385.46 and a 52 week high of $610.97. The company has a current ratio of 1.93, a quick ratio of 1.50 and a debt-to-equity ratio of 0.65.

Thermo Fisher Scientific (NYSE:TMO) last announced its quarterly earnings results on Wednesday, July 23rd. The medical research company reported $5.36 EPS for the quarter, topping the consensus estimate of $5.22 by $0.14. The company had revenue of $10.86 billion during the quarter, compared to analyst estimates of $10.68 billion. Thermo Fisher Scientific had a return on equity of 16.82% and a net margin of 15.24%.The firm’s revenue was up 2.9% on a year-over-year basis. During the same period in the prior year, the firm posted $5.37 earnings per share. Thermo Fisher Scientific has set its Q3 2025 guidance at 5.460-5.510 EPS. FY 2025 guidance at 22.220-22.840 EPS. Equities research analysts anticipate that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current year.

Analyst Ratings Changes

Several analysts have recently issued reports on the company. Royal Bank Of Canada set a $561.00 price objective on Thermo Fisher Scientific and gave the company an “outperform” rating in a research report on Tuesday, September 2nd. Hsbc Global Res downgraded Thermo Fisher Scientific from a “strong-buy” rating to a “hold” rating in a research report on Thursday, July 24th. Redburn Partners set a $580.00 price objective on Thermo Fisher Scientific in a research report on Wednesday, October 8th. Wells Fargo & Company reduced their price objective on Thermo Fisher Scientific from $570.00 to $565.00 and set an “overweight” rating on the stock in a research report on Thursday, July 24th. Finally, UBS Group upped their target price on Thermo Fisher Scientific from $460.00 to $500.00 and gave the company a “neutral” rating in a research note on Thursday, July 24th. Fifteen investment analysts have rated the stock with a Buy rating and six have given a Hold rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $589.10.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.